Hariyanto: Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies

Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies

Hariyanto et al., Reviews In Medical Virology, doi:10.1002/rmv.2265 (meta analysis)

Hariyanto et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical.., Reviews In Medical Virology, doi:10.1002/rmv.2265 (meta analysis)

Jun 2021 Source PDF

Twitter
Facebook

All Studies Meta

Systematic review and meta analysis of 19 RCTs showing mortality RR 0.31 [0.15-0.62].

Currently there are 95 ivermectin studies and meta analysis shows:

Outcome	Improvement
Mortality	51% lower [37‑62%]
Ventilation	29% lower [13‑42%]
ICU admission	41% lower [16‑58%]
Hospitalization	34% lower [20‑45%]
Cases	78% fewer [67‑85%]

Important missing comments or errors? Let us know.

risk of death, 69.0% lower, RR 0.31, p = 0.001.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Hariyanto et al., 6 Jun 2021, peer-reviewed, 5 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit